Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.
Graziela Zibetti Dal MolinCarina Meira AbrahãoRobert L ColemanFernando Cotait Maluf
Published in: Gynecologic oncology research and practice (2018)
Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention.